Pridopidine, 多巴胺 D2 受体调节剂

小分子

普利多比定

Pridopidine

P655560-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

Pridopidine 是一种多巴胺 (DA) 稳定剂，可用作一种低亲和力的多巴胺 D2 受体 (D2R) 拮抗剂。Pridopidine 高亲和力作用于 sigma 1受体 (S1R)，Ki 值为 70 到 80 nM，比其对 D2R 的亲和力高约 100 倍。 Pridopidine, a dopamine ( DA ) stabilizer, acts as a low affinity dopamine D2 receptor ( D2R ) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor ( S1R ) with K i between 70 and 80 nM, which is ~100× higher than its affinity toward D2R. In Vitro Pridopidine, a dopamine (DA) stabilizer, Pridopidine may be a neuromodulatory agent with neuroprotective properties in Huntington disease (HD). To clarify the neuroprotective efficacy of Pridopidine and to explore the potential underling molecular mechanism, the ability of Pridopidine is evaluated to protect cells from apoptosis and to eventually activate pro-survival targets. Administration of Pridopidine (150 μM), the most effective dose, significantly reduces apoptosis in immortalized striatal knock-in cells expressing endogenous levels of mutant Htt (STHdh 111/111 ) and markedly enhances phosphorylation state of prosurvival kinase ERK. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Pridopidine is known to act as a low affinity D2R antagonist. Pridopidine’s activity may be attributed to binding the sigma 1 receptor (S1R), an endoplasmic reticulum (ER). To strengthen the hypothesis that the BDNF pathway is upregulated due to activation of the S1R, SD rats are treated with lower doses of Pridopidine (range 0.3-60 mg/kg), and analysed the expression of seven selected genes in the BDNF pathway by qPCR. Pridopidine doses of 3 and 15 mg/kg in rats occupy 57±2% and 85±2% of S1R, respectively, and both do not show occupancy of the D2R, as determined by in vivo PET imaging. The significant occupancy proportion of the D2R (44-66%) is observed only at a dose of 60 mg/kg. This PET study supports the conclusion that the upregulation of genes in rats treated with 15 mg/kg Pridopidine are a result of specific activation of the S1R. At 30 mg/kg, partial/low occupancy of the D2R is at levels of 22-33% (assuming linearity), and S1R is saturated. Indeed, qPCR analysis reveals that the upregulation of EGR1 (already up at 3 mg/kg), EGR2, HOMER1A, KLF5, and ARC expression are upregulated at the low 15 mg/kg dose and expression of CDNK1A and CEBPB are significantly upregulated from a low dose of 30 mg/kg (CEBPB is significantly increased at 3 mg/kg but not at 15 mg/kg) . To further confirm the beneficial effect of Pridopidine on HD motor phenotype and to elucidate whether Pridopidine may act also as neuroprotective agent, preclinical studies in R6/2 mice have been undertaken. Daily administration of Pridopidine at a dose of 5 mg/kg, the most effective dose with no adverse effects, starting at the pre-symptomatic stage at 5 weeks for 6 weeks, significantly preserves motor function and prevents the progressive and dramatic motor worsening commonly observed in R6/2 mice. The beneficial effects of Pridopidine are maintained for about 4 weeks, after which mice show a slight worsening in performing both the horizontal ladder task and the open field. In addition, according to a Kaplan-Meier survival curve analysis, Pridopidine efficiently extends lifespan in the same mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Assay Conditionally immortalized mouse striatal knock-in cells expressing endogenous levels of wild-type (STHdh 7/7 ) or mHtt (STHdh 111/111 ) are used. Different concentrations of Pridopidine (100, 150, 200 and 300 μM) are tested to investigate the anti-apoptotic effect of the molecule on immortalized cells cultured in serum-free medium at 39°C for six hours. In NE100 experiments, cells are pre-incubated with the compound (10 μM) for 2 hrs before culturing them in apoptotic conditions. At the end of each treatment, cells are collected and incubated with FITC-conjugated Annexin V. Fluorescence Activated Cell Sorting (FACS) analysis is performed. MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:D 2 Receptor

普利多哌啶是一种多巴胺（DA）稳定剂，是一种低亲和力的多巴胺 D2 受体（D2R）拮抗剂。普利多哌啶对 sigma 1 受体（S1R）具有高亲和力，K i 在 70 至 80 nM 之间，比其对 D2R 的亲和力高出约 100 倍。

346688-38-8(DMSO)

C15H23NO2S

281.41 g/mol

CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C

调节剂

多巴胺 D2 受体调节剂